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Abstract
 
Clonal anergy of autoreactive B cells is a key mechanism regulating tolerance. Here, we show
that anergic B cells express significant surface levels of CD5, a molecule normally found on T
cells and a subset of B-1 cells. Breeding of the hen egg lysozyme (HEL) transgenic model for B
cell anergy onto the CD5 null background resulted in a spontaneous loss of B cell tolerance in
vivo. Evidence for this included elevated levels of anti-HEL immunoglobulin M (IgM) anti-
bodies in the serum of CD5
 
2
 
/
 
2
 
 mice transgenic for both an HEL-specific B cell receptor
(BCR) and soluble lysozyme. “Anergic” B cells lacking CD5 also showed enhanced prolifera-
tive responses in vitro and elevated intracellular Ca
 
2
 
1
 
 levels at rest and after IgM cross-linking.
These data support the hypothesis that CD5 negatively regulates Ig receptor signaling in aner-
gic B cells and functions to inhibit autoimmune B cell responses.
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Introduction
 
CD5 is a 67-kD transmembrane glycoprotein expressed
constitutively on T cells and a subset of B cells, referred to
as B-1a cells, that reside preferentially in the pleural and
peritoneal cavities (1–3). CD5 levels are developmentally
regulated in the T lineage, and correlate with the strength
of signaling through the TCR (4, 5). On normal peripheral
B cells, CD5 expression can be induced after surface IgM
cross-linking and B cell activation (6).
Studies with CD5 deficient mice suggest a possible role
for the molecule in negative regulation of lymphocyte anti-
gen receptor signaling (7). In CD5
 
2
 
/
 
2
 
 mice, TCR trans-
genic (Tg)
 
1
 
 CD4
 
1
 
CD8
 
1
 
 thymocytes were hyperresponsive
to selecting ligands, indicating that CD5 may regulate the
threshold for positive and negative selection (8). Although
normal peritoneal B-1 cells undergo apoptosis after cross-
linking of surface IgM receptors (9), the same treatment of
CD5-deficient B-1 cells resulted in enhanced Ca
 
2
 
1
 
 mobili-
zation and resistance to apoptosis (10). Despite these in-
sights, the precise role for CD5 in regulating immune re-
sponses remains unclear.
The hen egg lysozyme (HEL) Tg model system has
proven useful for investigating issues of tolerance in the B
lineage (11–14). In mice transgenic for both an Ig receptor
 
specific for HEL (HEL-Ig) and a membrane-bound self-
antigen (mHEL), B cells arrest in development in the bone
marrow and then undergo clonal deletion (15, 16). In con-
trast, mice transgenic for HEL-Ig and a soluble form of the
self-antigen HEL (sHEL) generate B cells that are function-
ally impaired, or anergic. Only background levels of serum
anti-HEL IgM Abs are produced in these anergic animals,
and the B cells display downregulated surface IgM levels
and are unresponsive to further stimulation through the B
cell receptor (BCR) (11–14). In the experiments described
here, we show that CD5 is expressed at higher levels on
HEL-Ig/sHEL anergic B cells than on naive HEL-Ig B
cells, most likely as a consequence of chronic BCR stimu-
lation. By breeding both HEL-Ig and sHEL transgenes
onto the CD5-deficient background, we demonstrate that
the level of CD5 expressed on anergic B cells is important
for maintaining tolerance to self-antigen.
 
Materials and Methods
 
Mice.
 
MD4 HEL-Ig and ML5 sHEL Tg mice were originally
obtained from Dr. C. Goodnow (Australian National University,
Canberra, Australia), and were genotyped as described (11, 17).
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Abbreviations used in this paper:
 
 [Ca
 
2
 
1
 
]
 
i
 
, intracellular calcium concentra-
tion; BCR, B cell receptor; HEL, hen egg lysozyme; MFI, mean fluores-
cence intensity; mHEL, membrane-bound self-antigen HEL; sHEL, solu-
ble self-antigen HEL; SHP-1, Src homology 2 domain–containing
protein tyrosine phosphatase 1; Tg, transgenic. 
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CD5 knockout mice were provided by A. Tarakhovsky (Univer-
sity of Cologne, Cologne, Germany) and Randy Hardy (Fox
Chase Cancer Center, Philadelphia, PA). The HEL-Ig (IgM
 
a
 
allotype) and sHEL transgenes were crossed onto the CD5
 
2
 
/
 
2
 
background, and the resulting CD5
 
1
 
/
 
2
 
 and CD5
 
2
 
/
 
2
 
 animals were
on essentially identical mixed genetic backgrounds (
 
z
 
25% 129/Sv
and 
 
z
 
75% C57Bl/6J). The CD5
 
1
 
/
 
1
 
 
 
HEL-Ig and HEL-Ig/sHEL
Tg animals used in these experiments were 100% C57Bl/6J. CD5
null offspring were identified by flow cytometry of peripheral
blood using anti-CD5 mAbs (PharMingen) or by PCR genotyp-
ing of tail DNA. All mice were maintained in specific pathogen-
free isolation at the University of Minnesota animal facility, and
were used at 8–12 wk of age.
 
Flow Cytometric Analysis.
 
Single cell lymphoid populations
were prepared as described (17), and were stained with FITC–
anti-IgM
 
a
 
, PE–anti-CD5, and CyChrome–anti-B220 mAbs, or
appropriate IgG2a control mAbs (all mAbs from PharMingen) for
flow cytometric analysis. To identify HEL-binding B cells, a
modified HEL sandwich assay was used. In brief, cells were incu-
bated with 10 
 
m
 
g/ml HEL (Sigma Chemical Co.), washed, and
then incubated with biotinylated D1.3 anti-HEL mAbs (18). Af-
ter washing, the bound D1.3 anti-HEL Abs were detected with
allophycocyanin (APC)-streptavidin. Three- and four-color flow
cytometry was performed using a FACSCalibur™ (Becton Dick-
inson), and data were analyzed using Flowjo software (Treestar).
 
Serum anti-HEL IgM ELISAs.
 
Sera from HEL-Ig and HEL-
Ig/sHEL mice of the various CD5 genotypes were collected by
eye or tail bleed, and anti-HEL IgM
 
a
 
 levels were measured by
specific ELISA (12, 17). Sera were diluted 500- or 2,500-fold for
measurement in HEL-Ig mice, and 100- or 500-fold for HEL-Ig/
sHEL animals. Relative serum anti-HEL IgM
 
a
 
 levels were calcu-
lated as the product of the mean OD 490 of triplicate samples and
the dilution.
 
In Vitro Assays.
 
B cells were enriched from single cell spleen
preparations using anti–Thy-1 magnetic beads (Dynal) to deplete
T cells. The resulting B cells from HEL-Ig or HEL-Ig/sHEL
mice were cultured in triplicate wells (10
 
5
 
 cells/200 
 
m
 
l medium)
in complete RPMI 10%/FCS medium in the absence or presence
of rIL-4 (10 ng/ml) and/or anti-
 
m
 
 polyclonal F(ab
 
9
 
)
 
2
 
 Abs (10 
 
m
 
g/
 
ml) for 3 d. [
 
3
 
H]Thymidine incorporation was measured for the
last 16 h of culture. For calcium mobilization studies, splenocytes
were purified by red blood cell lysis, loaded with indo-1 (5 
 
m
 
M;
Molecular Probes) at 37
 
8
 
C (19), and stained with PE-labeled anti-
B220 (PharMingen) at 4
 
8
 
C. After washing, cells were warmed to
37
 
8
 
C for 3 min before analysis. Intracellular calcium ([Ca
 
2
 
1
 
]
 
i
 
) lev-
els of splenocytes were then acquired for 30 s to assure a stable
baseline, and the cells were stimulated by the addition of 10 
 
m
 
g/
ml anti-
 
m
 
 Abs. [Ca
 
2
 
1
 
]
 
i
 
 levels were measured as the ratio of indo-1
fluorescence at 395 versus 530 nm of gated B220
 
1
 
 cells.
 
Results and Discussion
 
CD5 Expression on Anergic B Cells.
 
We recently reported
that the antiapoptotic gene
 
 bcl-x
 
L
 
, when overexpressed as a
transgene, allowed HEL-Ig B cells to escape central dele-
tion in mHEL mice (17). The escaped B cells were pro-
foundly anergic, and surprisingly were found to express sig-
nificant levels of cell surface CD5 (our unpublished data).
Thus, we tested whether B cells in HEL-Ig/sHEL double
Tg mice, the prototypic model for B cell anergy, also ex-
pressed CD5. By flow cytometry, anergic B cells (HEL-Ig/
sHEL, B220
 
1
 
; HEL-binding, IgM
 
a-low
 
) expressed signifi-
cantly higher levels of CD5 than HEL-Ig B cells (Fig. 1 A).
In 10 pairs of mice tested, there was a mean 3.6 
 
6 
 
0.4–fold
increase in CD5 levels in HEL-Ig/sHEL B cells compared
with HEL-Ig B cells (Fig. 1 C,
 
 P 
 
, 
 
0.001 by Student’s
paired 
 
t
 
 test). The level of CD5 expressed on anergic HEL-
Ig/sHEL B cells was intermediate between the low levels
found on HEL-Ig B cells and the higher levels on control
peritoneal B-1a cells (Fig. 1, B and C). By comparison,
CD5 expression on splenic T cells (Fig. 1 A; T cells are
CD5
 
hi
 
, B220
 
2
 
) was 
 
z
 
10-fold higher than on peritoneal
B-1a and 50-fold higher than on anergic B cells. The mean
fluorescence intensities (MFIs) of CD5 on each of the rele-
vant cell types are summarized in Fig. 1 C.
Figure 1. CD5 expression on
anergic B cells. (A) Splenocytes
from CD51/1 and CD52/2
HEL-Ig (Ig) or HEL-Ig/sHEL
(Ig/sHEL) mice were stained
with anti-IgMa, anti-CD5, anti-
B220, and/or control IgG2a
mAbs, and analyzed by flow cy-
tometry. Results show lym-
phoid cells gated on the basis of
forward by side scatter. All sam-
ples were analyzed in parallel
using identical cytometer set-
tings. Quadrant settings were
placed to allow comparison of
the relative levels of CD5,
HEL-binding, and IgMa. (B)
Overlaid histograms of CD5
expression on HEL-Ig (Ig, dot-
ted line), HEL-Ig/sHEL (Ig/
sHEL, bold line), and C57Bl/6J
control peritoneal B-1a cells (wt
B-1a, light line). HEL-Ig and
HEL-Ig/sHEL B cells were gated on B2201IgMa1 cells, and B-1a cells were gated on B220loIgMhi cells. (C) CD5 MFIs (6SD) for the indicated cell
populations are shown (n 5 10, except for peritoneal B-1a cells where n 5 4). 
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Breeding of HEL-Ig and sHEL Transgenes onto the CD5
 
2
 
/
 
2
 
Background.
 
To determine the functional significance of
CD5 expression on anergic B cells, the HEL-Ig and sHEL
transgenes were backcrossed onto the CD5 null back-
ground. As expected, B and T cell populations in the re-
sulting CD5
 
2
 
/
 
2
 
 mice showed no detectable expression of
CD5 (Fig. 1 A, bottom). The levels of HEL-binding IgM
 
a
 
were similar on CD5
 
1
 
/
 
1
 
 compared with CD5
 
2
 
/
 
2
 
 HEL-Ig
or HEL-Ig/sHEL B cells in the bone marrow, spleen, and
lymph nodes (Fig. 1, and data not shown). We also ob-
served no CD5-dependent differences in expression of the
maturity markers CD21, CD22, CD23, or CD24 on HEL-Ig
or HEL-Ig/sHEL B cells (data not shown).
Interestingly, the level of CD5 expressed on naive
CD5
 
1
 
/
 
1
 
 
 
HEL-Ig B cells was slightly higher than the iso-
type control mAb staining and was also above that ob-
served on CD5
 
2
 
/
 
2
 
 HEL-Ig B cells (Fig. 1, A and C). In
the original report describing the phenotype of CD5
 
2
 
/
 
2
 
mice, Tarakhovsky and colleagues also noted this low level
CD5 staining on naive splenic B cells (7). They suggested
that this staining might represent passive acquisition of sol-
uble CD5 shed by CD5
 
1
 
 
 
T cells, since this low level of
CD5 on B cells was not observed in T cell–deficient 
 
nu/nu
 
mice. Regardless of the source of the “background” CD5
expression on naive B cells, the data shown in Fig. 1 dem-
onstrate that HEL-Ig/sHEL B cells have increased surface
levels of CD5 compared with antigen naive HEL-Ig B
cells. This difference is unlikely to be accounted for by
passive acquisition from T cells, as the T cells in both cases
are wild-type for CD5.
 
Anergic CD5
 
2
 
/
 
2
 
 Mice Have Fewer B Cells in Spleen and
Blood.
 
Table I shows the size of B cell populations in the
various mice generated. CD5 genotype had no effect on B
 
cell populations in HEL-Ig mice, and the numbers of bone
marrow B220
 
1
 
 B cells were similar in CD5
 
1
 
/
 
1
 
 and CD5
 
2
 
/
 
2
 
HEL-Ig/sHEL mice. In CD5
 
1
 
/
 
1
 
 mice, B cell numbers in
the spleen of HEL-Ig/sHEL mice were decreased by 
 
z
 
50%
compared with HEL-Ig mice, as reported previously (14,
20). In addition, there were significantly fewer splenic IgM
 
a
 
1
 
B cells in CD5
 
2
 
/
 
2
 
 HEL-Ig/sHEL mice compared with
CD5
 
1
 
/
 
1
 
 double Tg controls. A diminished percentage of B
cells in the blood of CD5
 
2
 
/
 
2
 
 HEL-Ig/sHEL mice was also
noted. This phenotype was similar to the reduced peripheral
B cell pool reported in HEL-Ig/sHEL mice with deficiencies
in negative regulators of BCR signaling (lyn, CD22, and Src
homology 2 domain–containing protein tyrosine phos-
phatase [SHP-1]; references 20, 21), or overexpressing the
BCR costimulatory molecule CD19 (22).
 
Spontaneous Secretion of Autoantibodies in Anergic CD5
 
2
 
/
 
2
 
Mice.
 
Despite the lower numbers of IgM
 
a
 
1
 
 B cells in HEL-
Ig/sHEL mice on the CD5 null background, many of these
animals exhibited elevated levels of anti-HEL IgM
 
a
 
 Abs in
serum (Fig. 2). Although specific Ab levels in CD5
 
1
 
/
 
1
 
 and
CD5
 
1
 
/
 
2
 
 HEL-Ig/sHEL mice were consistently near or be-
low the limit of detection, 13 of 29 CD5
 
2
 
/
 
2
 
 HEL-Ig/sHEL
mice tested demonstrated anti-HEL IgM
 
a titers above the
highest level measured in CD51/1 or CD51/2 anergic mice.
Remarkably, the titers in 4 of 29 mice were within the range
observed for HEL-Ig mice. Thus, many of the “anergic”
mice lacking CD5 showed a spontaneous in vivo loss of B
cell tolerance.
Serial bleeds of CD52/2 HEL-Ig/sHEL mice indicated
that levels of serum anti-HEL Abs remained stable over a
period of at least 4 mo. In preliminary experiments, we im-
munized CD52/2 HEL-Ig/sHEL mice that displayed low
basal levels of HEL-specific IgM with HEL in adjuvant to
Table I. B Cell Populations in CD51/1 and CD52/2 HEL-Ig and HEL-Ig/sHEL Mice
Cell numbers (31026)
Cells CD51/1 HEL-Ig CD52/2 HEL-Ig CD51/1 HEL-Ig/sHEL CD52/2 HEL-Ig/sHEL
Bone marrow (n 5 3)
Total cellularity 46 6 1 46 6 16 49 6 6 36 6 5
B2201IgMa2 0.5 6 0.1 0.5 6 0.2 0.4 6 0.1 0.5 6 0.0
B2201IgMa1 3.3 6 0.2 4.3 6 1.9 3.3 6 0.9 2.8 6 0.5
Spleen (n 5 6)
Total cellularity 58 6 7 56 6 6 42 6 4* 39 6 9*
B2201IgMa1 26 6 6 23 6 5 11 6 3* 5 6 1*‡
Blood (n 5 6)§ 14 6 3 15 6 3 12 6 13  6 1i
Single cell suspensions of bone marrow (both femurs and tibias) and spleen were enumerated, and B220/IgMa subpopulations were identified using 
flow cytometry. Data represent mean 6 SEM for each group of mice analyzed in parallel at 8–12 wk of age. Student’s paired t test was used for 
statistical comparisons.
*Fewer total splenocytes and B2201IgMa1 splenic B cells in CD51/1 and CD52/2 HEL-Ig/sHEL mice compared with Ig controls. CD51/1 HEL-
Ig/sHEL vs. CD51/1 HEL-Ig: total splenocytes, P , 0.03; B cells, P , 0.03. CD52/2 HEL-Ig/sHEL vs. CD52/2 HEL-Ig: total splenocytes, P ,
0.02; B cells, P , 0.003.
‡Fewer B2201IgMa1 splenic B cells in CD52/2 vs. CD51/1 HEL-Ig/sHEL mice; P , 0.03.
§Data for blood are expressed as percent B2201 instead of cell numbers.
iLower percentage of B2201 B cells in the blood of CD52/2 vs. CD51/1 HEL-Ig/sHEL mice; P , 0.001.886 CD5 and Anergic B Cells
test whether tolerance could be broken in these animals. In
approximately half the mice, immunization led to a .18-
fold increase in anti-HEL titers at 14 d, compared with no
more than 2-fold increases in control CD51/1 anergic mice
(our unpublished data). The reason for the heterogeneity ob-
served in Ab responses (both basal and induced) in CD52/2
HEL-Ig/sHEL animals is currently unknown. One possibil-
ity is that this reflects subtle differences in background genes,
since these animals are on a mixed 129/B6 background, and
the 129/Sv genetic background has recently been shown to
be permissive for autoantibody production in other knock-
out models (23, 24). Alternatively, this heterogeneity might
reflect differing exposure of the mice to infectious agents, or
incomplete penetrance of the CD5 genetic effect.
CD52/2 HEL-Ig/sHEL B Cells Are Hyperproliferative in Re-
sponse to BCR Cross-linking. A hallmark of B cell anergy is
reduced in vitro proliferation in response to antigen or BCR
cross-linking (12, 14). Therefore, we isolated splenic B cells
from CD51/1 and CD52/2 HEL-Ig and HEL-Ig/sHEL mice
and stimulated them in vitro with anti-m Abs in the presence
of IL-4, followed by measurement of DNA synthesis. In the
representative experiment shown (Fig. 3 A), purified B cells
from CD52/2 HEL-Ig mice showed approximately a twofold
greater proliferative response than CD51/1 HEL-Ig animals
after anti-m or anti-m plus IL-4 treatment. This result differs
from previous published data (10), where the proliferation of
stimulated polyclonal CD51/1 and CD52/2 B-2 cells was re-
ported to be similar. These differences are likely attributable
to the fact that we are studying the responses of Ig transgenic
B cells, where the activation state and response to stimulation
may be more uniform, and/or to technical differences in the
preparation of the B cells. Importantly, CD52/2 HEL-Ig/
sHEL B cells demonstrated an eightfold increase in prolifera-
tion compared with CD51/1 anergic cells in response to
anti-m plus IL-4. In other experiments, this fold increase
ranged from 4 to 14. Thus, CD52/2 “anergic” B cells, and
even CD52/2 HEL-Ig cells, were hyperproliferative after
BCR cross-linking, suggesting that CD5 functions to down-
regulate BCR signaling in these cells.
Calcium Responses in CD52/2 B Cells. To begin to address
the molecular nature of the dysregulated responses observed
in CD52/2 HEL-Ig/sHEL B cells, we measured [Ca21]i lev-
els by flow cytometry using indo-1 (19), both in resting and
anti-m–stimulated B cells. Previous work has shown that B
cells from anergic HEL-Ig/sHEL mice have a higher resting
[Ca21]i than HEL-Ig mice (25, 26), and this was confirmed
here (Fig. 3, B and C). Interestingly, the mean basal [Ca21]i
of CD52/2 HEL-Ig/sHEL B cells was 36% higher than
Figure 2. Elevated serum anti-HEL IgMa Ab levels in CD52/2 HEL-
Ig/sHEL mice. Sera from CD51/1, CD51/2, or CD52/2 HEL-Ig and
HEL-Ig/sHEL mice were collected, and anti-HEL IgMa levels were mea-
sured by specific ELISA. All samples were analyzed in parallel. Each data
point represents the mean value for a single mouse, while horizontal bars
indicate the mean value for each group of animals. Differences in mean
anti-HEL IgMa levels between CD52/2 and either CD51/2 or CD51/1
HEL-Ig/sHEL mice were significant (P , 0.02, Student’s paired t test).
Figure 3. (A) Proliferative responses of splenic B cells in vitro. B cells
from CD51/1 or CD52/2 HEL-Ig (top) or HEL-Ig/sHEL (bottom) mice
were cultured in triplicate in the absence or presence of rIL-4 (10 ng/ml)
and/or anti-m polyclonal F(ab9)2 Abs (10 mg/ml) for 3 d. [3H]Thymidine
incorporation was measured for the last 16 h of culture. Data represent
mean 6 SD of the triplicate cultures, and are representative of six experi-
ments. (B and C) Elevated resting and stimulated [Ca21]i levels in CD52/2
HEL-Ig/sHEL B cells. Indo-1–loaded splenocytes from CD51/1 and
CD52/2 HEL-Ig or HEL-Ig/sHEL mice were stained with anti-B220
mAbs, and [Ca21]i of B2201 B cells was measured at rest and after stimu-
lation with 10 mg/ml anti-m Abs (break in tracing). The data shown are
representative of five independent experiments. C summarizes data from
six experiments (mean 6 SEM), showing relative resting [Ca11]i of gated
B cells, with the indo-1 ratio for HEL-Ig B cells set at 100%.887 Hippen et al.
CD51/1 HEL-Ig B cells (P , 0.004) and 22% higher than
CD51/1 HEL-Ig/sHEL B cells (P , 0.006) (Fig. 3 C).
Anti-m stimulation resulted in rapid and sustained Ca21
mobilization in CD51/1 and CD52/2 HEL-Ig B cells (Fig.
3 B, top; differences in the curves after the 100-s time point
were not always observed). Neither CD51/1 nor CD52/2
HEL-Ig/sHEL B cells responded to soluble HEL protein by
mobilizing Ca21 (data not shown). Similarly, anti-m stimula-
tion, which provides higher levels of Ig cross-linking, failed
to induce a significant Ca21 flux in CD51/1 HEL-Ig/sHEL
B cells (Fig. 3 B, bottom). However, anti-m induced a rapid
Ca21 mobilization in CD52/2 HEL-Ig/sHEL B cells that
peaked at levels equivalent to HEL-Ig B cells, and then
drifted slowly towards baseline.
These results indicate that the levels of CD5 expressed on
anergic B cells are functionally important for maintaining B
cell tolerance. Approximately half of the HEL-Ig/sHEL
mice lacking CD5 exhibited spontaneously elevated levels of
serum anti-HEL IgMa, and purified B cells from CD52/2
anergic mice were hyperresponsive in vitro. This observed
break in B cell tolerance is most likely due to an increased
sensitivity of the anti-HEL BCR to cross-linking in the ab-
sence of CD5. Although the signaling pathways downstream
of CD5 are not well defined, it was recently reported that
SHP-1, a phosphatase that negatively regulates Ig signaling
(20, 21, 27–29), associates with the CD5 cytoplasmic do-
main (30, 31). In the absence of CD5, B cells with chroni-
cally engaged BCRs may have insufficient SHP-1 (or other
negative regulators) available at the membrane to downmod-
ulate BCR signaling, leading to the observed phenotype.
The data presented do not exclude the possibility that de-
fects in T cell tolerance may be contributing to the observed
phenotype in CD52/2 HEL-Ig/sHEL mice. However, sev-
eral lines of evidence suggest that the phenotype is more
likely to reflect an intrinsic defect in CD52/2 HEL-Ig/sHEL
B cells. First, in the data shown in Fig. 3, CD52/2 HEL-Ig/
sHEL B cells fluxed calcium in response to BCR cross-link-
ing while CD51/1 anergic B cells did not, and T cell–depleted
splenic HEL-Ig/sHEL B cells from CD52/2 mice were hy-
perproliferative in response to BCR cross-linking compared
with CD51/1 anergic B cells. BCR cross-linking in both these
settings is T cell independent, suggesting an intrinsic defect
in B cells. Also arguing against a significant role for T cells in
this system are data from previous studies showing exquisite
sensitivity of HEL-reactive T cells to negative selection in
mice expressing even very low levels of soluble HEL (32,
33). Finally, while CD5 likely does have a role in fine tuning
selection events in the thymus (5, 8), Tarakhovsky and col-
leagues reported that negative selection of H-Y–specific
TCR transgenic T cells was not affected in male CD52/2
H-Y Tg mice (8). To more definitively address the issue of
T cell tolerance in this model, we are currently breeding the
CD5 knockout alleles and the HEL-Ig and sHEL transgenes
onto the T cell–deficient recombination activating gene
(Rag) knockout background.
Although CD5 can be induced on mature peripheral B
cells after activation (3), constitutive expression of CD5 in
the B lineage (above that found on naive B cells; see Fig. 1)
has previously been observed only on the B-1a population.
B-1a cells are found in the serous cavities of mice and hu-
mans, including the peritoneum, and they comprise a signif-
icant percentage of peripheral B cells in humans (34, 35). B-1
cells are a major source of natural autoantibody production,
and require antigen exposure for their maturation into Ab-
secreting cells (36). Although B-1 cells are not anergic as
classically defined in the HEL system, there are some inter-
esting parallels. Both populations have received antigen
stimulation (12, 36), both cell types respond suboptimally to
IgM cross-linking (9, 14), and both show evidence for ex-
cessive receptor editing (17, 37; and Tze, L.E., and T.W.
Behrens, unpublished data). In addition, B-1 cells generally
use germline-encoded heavy and light chain V genes with
little evidence for somatic mutation and are reported to be
excluded from germinal centers (34, 35). Likewise, anergic
cells are excluded from follicles (38), and thus are unable to
effectively participate in germinal center responses. These
similarities raise the possibility that B cell anergy, or an an-
ergy-like state, might be an intermediate step in the devel-
opment of the B-1 compartment.
The hypothesis that low-to-intermediate levels of CD5
identify B cells with a history of antigen exposure has po-
tentially interesting implications for human disease. The
numbers of peripheral CD51 B cells are increased in several
autoimmune diseases, including rheumatoid arthritis, pri-
mary Sjogren’s syndrome, autoimmune thyroid disease,
and multiple sclerosis (39). The accumulation of CD51 B
cells in autoimmunity may, at least in part, be secondary to
antigen-driven activation and subsequent anergy induction
of autoreactive B cells. Mechanisms that then contribute to a
loss of tolerance in CD51 anergic B cells, including polymor-
phisms in molecules that negatively regulate BCR signaling,
might be important in the pathogenesis of autoimmune disor-
ders. Finally, .95% of human chronic lymphocytic leukemias
and many small cell non-Hodgkin’s lymphomas are derived
from a CD51 B cell precursor (40). Repeated encounters of
CD51 B cells with self-antigen and resultant chronic signaling
through the BCR might contribute to the genetic mutations
responsible for their malignant transformation.
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